Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of BeOne Medicines Ltd.. A complete text table follows the diagram.
BRUKINSA has become a $1.1B quarterly global franchise, while TEVIMBRA and licensed oncology medicines form the next layer
Swipe to explore
XGEVA, BLINCYTO and KYPROLIS are grouped as licensed Amgen medicines using exact reported product values. POBEVCY is licensed from Bio-Thera. BRUKINSA and TEVIMBRA are internally developed products.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Net product revenue | 1 | $1.5B | Up 34% year over year |
| BRUKINSA | 2 | $1.1B | 74% of product revenue |
| TEVIMBRA | 2 | $206M | Internally developed oncology medicine |
| Amgen-licensed medicines | 2 | $141M | XGEVA, BLINCYTO and KYPROLIS |
| POBEVCY | 2 | $12.1M | Bio-Thera-licensed medicine |
| Other products | 2 | $33.2M | Remaining reported portfolio |
| From | To | Value |
|---|---|---|
| Net product revenue | BRUKINSA | $1.1B |
| Net product revenue | TEVIMBRA | $206M |
| Net product revenue | Amgen-licensed medicines | $141M |
| Net product revenue | POBEVCY | $12.1M |
| Net product revenue | Other products | $33.2M |